| MCK |
Report |
Adjusted EPS (Q1 FY27) |
BEAT |
pred ~$9.60 vs. cons $9.46 |
MEDIUM |
| MCK |
Report |
Total Revenue (Q1 FY27) |
MISS |
pred ~$102.8B vs. cons $104.25B |
MEDIUM |
| MCK |
Report |
North America Pharmaceutical segment revenue growth (y/y) |
MISS |
pred ~4.0% vs. cons/guide-midpoint ~6.0% |
MEDIUM |
| MCK |
Guide |
FY2027 Adjusted EPS guidance |
UNCHANGED |
guide ~$44.20 midpoint vs. cons ~$44.05 (FY2027) |
MEDIUM |
| MCK |
Guide |
FY2027 Consolidated revenue growth guidance |
UNCHANGED |
guide ~7.0% (5-9% range midpoint) vs. cons 6.6% (FY2027) |
LOW |
| MCK |
Guide |
FY2027 Adjusted operating profit growth guidance |
UNCHANGED |
guide ~10.0% (8-12% range midpoint) vs. cons ~9.5% (FY2027) |
LOW |
| MCK |
Guide |
FY2027 Free cash flow guidance |
LOWER |
guide ~$4.7B (4.5-4.9B range) vs. cons ~$4.9B (FY2027) |
LOW |
| MCK |
Guide |
MMS separation/IPO timeline commentary |
UNCHANGED |
guide ~2H CY2027 IPO target vs. cons 2H CY2027 expectation (FY2027-CY2027) |
MEDIUM |
| MCK |
Return |
Day-1 residual (stock − beta × S&P 500) |
-3.0% |
— |
MEDIUM |
| MCK |
Return |
5-day cumulative residual |
-5.0% (FADE) |
Even with a modest headline EPS beat, a revenue miss driven by branded-pricing/IRA headwinds and softer GLP-1 sequential trends in the largest segment (NA Pharmaceutical) implies downward pressure on out-quarter revenue and margin models; with FY27 guidance merely reaffirmed (not raised) against a stock priced near all-time highs on a rich relative multiple, sell-side is likely to trim FY27/FY28 revenue and FCF estimates even as EPS holds, producing continued multiple compression over the following days as the 'quality of beat' concern outweighs the EPS headline. |
MEDIUM |